• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Myocardial Ischemia Companies

    ID: MRFR/MED/4355-CR
    135 Pages
    Rahul Gotadki
    August 2019

    Myocardial ischemia is a medical condition characterized by reduced blood flow to the heart muscle, leading to inadequate oxygen supply. This can result in damage to the heart muscle and, if left untreated, can lead to more severe complications, such as a heart attack.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Myocardial Ischemia Market Research Report - Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Myocardial Ischemia Market

    Myocardial Ischemia Key Companies

     


    Latest Myocardial Ischemia Companies Update:

    Novartis' pelacarsen shows positive Phase 3 results in reducing recurrent events after myocardial infarction (MI): This novel investigational drug demonstrated potential in preventing subsequent heart attacks or hospitalizations for heart failure after an initial MI.


    Recardio's dutoglituplin reaches Phase 3 trial stage for stable angina: This glucagon-like peptide-1 receptor agonist aims to improve symptoms and quality of life in patients with chronic stable angina, a form of myocardial ischemia.


    Boehringer Ingelheim collaborates with Eli Lilly and Company on Jardiance for cardiovascular outcomes: This partnership expands the potential use of Jardiance, an SGLT2 inhibitor, for preventing major adverse cardiovascular events in patients with established cardiac risk factors, including myocardial ischemia.


    Medtronic acquires Fortive Corporation's Cardiovascular and Surgical Technologies business: This deal strengthens Medtronic's cardiac rhythm management and structural heart solutions portfolio, with a focus on minimally invasive therapies for angina and other ischemic conditions.


    List of Myocardial Ischemia Key companies in the market

    • Taxus Cardium (US)

    • ViroMed Co. Ltd. (Republic of Korea )

    • Edward Lifesciences (US)

    • Daiichi Sankyo Company Limited (Japan)

    • Boston Scientific Corporation (US)

    • Merck KGaA (Germany)

    • Novartis AG (Switzerland)

    • Boehringer Ingelheim International GmbH (Germany)

    • Johnson & Johnson Services Inc. (US)

    • Bayer AG (Germany)

    •  AstraZeneca (UK)